GILD Stock Recent News
GILD LATEST HEADLINES
Here is how Gilead Sciences (GILD) and Natera (NTRA) have performed compared to their sector so far this year.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 4 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 11 at 10:40 AM Eastern Time The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays will be available for at least 30 days following the.
The Investment Committee debate the Calls of the Day in two biotech names.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 19, 2025. Acceptance.
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive.
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70.
Shares of Gilead Sciences (GILD 7.14%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.